read
interest
correspond
christoph
green
colleagu
suggest
need
molecular
test
screen
faecal
microbiota
transplant
fmt
donor
sever
acut
respiratori
syndrom
coronaviru
prevent
potenti
risk
transmiss
march
us
food
drug
administr
fda
issu
safeti
alert
death
caus
transmiss
drugresist
escherichia
coli
bacteraemia
via
fmt
million
peopl
infect
screen
polici
fmt
donor
stringent
scientif
valid
presenc
includ
live
viru
stool
asymptomat
individu
impli
coronaviru
diseas
might
transmit
via
faecal
rout
develop
stool
test
slow
sinc
realtim
rtpcr
respiratori
sampl
typic
use
confirm
diagnosi
time
write
fda
recommend
fmt
product
gener
stool
donat
dec
use
proper
test
screen
protocol
avail
describ
green
colleagu
univers
birmingham
microbiota
treatment
centr
birmingham
uk
activ
process
new
donor
valid
stool
test
avail
fmt
centr
chines
univers
hong
kong
hong
kong
one
largest
provid
fmt
asia
sole
provid
fmt
health
author
hong
kong
although
first
case
report
hong
kong
jan
quarantin
donor
materi
donat
sinc
nov
use
develop
screen
protocol
combin
questionnair
identifi
donor
might
risk
infect
rtpcr
assay
detect
donor
stool
assay
panel
allow
viral
quantif
h
turnaround
valid
assay
stool
sampl
confirm
case
stool
sampl
asymptomat
noninfect
individu
return
highrisk
area
per
diagnost
protocol
local
health
author
case
confirm
two
rtpcr
test
target
differ
region
rdrp
gene
respiratori
specimen
confirm
case
posit
stool
test
median
two
stool
sampl
posit
per
patient
viral
load
log
copi
per
ml
stool
sampl
asymptomat
individu
test
posit
found
singl
neg
test
current
practic
screen
pathogen
insuffici
exclud
presenc
stool
recommend
test
donor
multipl
timepoint
donat
period
sinc
level
viral
rna
present
stool
fluctuat
around
margin
laboratori
detect
test
stool
done
appropri
equip
laboratori
train
staff
specimen
handl
would
requir
biosafeti
level
laboratori
equival
facil
enhanc
donor
screen
valid
stool
test
ensur
safe
effect
deliveri
fmt
critic
ill
patient
recurr
refractori
clostridioid
difficil
infect
